USA – FDA postpones DSCA provision enforcement by 3 years

The US Food and Drug Administration (FDA) last week announced it will again delay enforcement of a provision of the Drug Supply Chain Security Act (DSCSA) that would require wholesalers to verify saleable returned drugs they intend to further distribute.
“FDA does not intend to take action against wholesale distributors who do not, prior to November 27, 2023, verify the product identifier prior to further distributing returned product as required under section 582(c)(4)(D) of the [Federal Food, Drug, and Cosmetic Act] FD&C Act,” FDA writes.
The provision was originally slated to take effect last November, but FDA announced it would delay enforcement by one year in September 2019. (RELATED: FDA delays verification requirement for salable returned drugsRegulatory Focus 24 September 2019)…